Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Lymphoid 2Head & Neck 1Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 1Nephrotic Syndrome 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Bladder Cancer 1Kidney Diseases 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Carcinoma, Non-Small-Cell Lung 1Arthritis, Rheumatoid 1Amyloidosis 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Pharmaceutical Preparations × Genitourinary × Clear all
NCT00201630 2005-09-20

Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy

New York Prostate Institute

Phase 3 Unknown
150 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡